Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership

Rhea-AI Filing Summary

Capital International Investors reported beneficial ownership of Hemab Therapeutics Holdings, Inc. common stock on a Schedule 13G. The firm is deemed to beneficially own 3,603,876 shares, representing 7.7% of Hemab’s common stock, based on 46,705,410 shares believed to be outstanding. Capital International Investors has sole voting and sole dispositive power over all 3,603,876 shares and no shared voting or dispositive power.

Key Figures

Beneficially owned shares: 3,603,876 shares Ownership percentage: 7.7% Shares believed outstanding: 46,705,410 shares +2 more

5 metrics

Beneficially owned shares 3,603,876 shares Hemab Therapeutics common stock beneficially owned by Capital International Investors

Ownership percentage 7.7% Percent of Hemab Therapeutics common stock class reported as beneficially owned

Shares believed outstanding 46,705,410 shares Total Hemab Therapeutics shares believed to be outstanding used in 7.7% calculation

Sole voting power 3,603,876 shares Shares over which Capital International Investors has sole power to vote

Sole dispositive power 3,603,876 shares Shares over which Capital International Investors has sole power to dispose

Key Terms

beneficial owner, Sole power to vote or to direct the vote, dispositive power, CUSIP Number(s)

4 terms

beneficial owner financial

"CII is deemed to be the beneficial owner of 3,603,876 shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Sole power to vote or to direct the vote financial

"(i) Sole power to vote or to direct the vote: 3,603,876"

dispositive power financial

"(iii) Sole power to dispose or to direct the disposition of: 3,603,876"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

CUSIP Number(s) financial

"(e) | CUSIP Number(s): 423494103"

FAQ

What percentage of Hemab Therapeutics (COAG) does Capital International Investors own?

Capital International Investors reported beneficial ownership of 7.7% of Hemab Therapeutics Holdings, Inc. common stock, representing 3,603,876 shares out of 46,705,410 shares believed to be outstanding, according to the Schedule 13G filing.

How many Hemab Therapeutics (COAG) shares does Capital International Investors control?

Capital International Investors is deemed to beneficially own 3,603,876 shares of Hemab Therapeutics common stock, with sole voting and sole dispositive power over all of these shares and no shared voting or dispositive authority.

Does Capital International Investors share voting power over Hemab Therapeutics (COAG) shares?

No. The filing states Capital International Investors has sole power to vote or direct the vote over 3,603,876 shares and shared voting power of 0, indicating all reported voting authority is held solely.

What is the total Hemab Therapeutics (COAG) share count used in this 13G?

Capital International Investors’ 7.7% ownership is calculated against 46,705,410 shares of Hemab Therapeutics common stock that are believed to be outstanding, as referenced in the Schedule 13G ownership calculation.

Who signed the Schedule 13G for Hemab Therapeutics (COAG)?

The Schedule 13G was signed by Aaron Espin, identified as Senior Vice President, on 07/29/2026, acting on behalf of Capital International Investors regarding its beneficial ownership in Hemab Therapeutics common stock.

Which other party is mentioned in relation to Hemab Therapeutics (COAG) ownership?

The filing references SMALLCAP World Fund, Inc. under the item addressing ownership of more than 5 percent on behalf of another person, in the context of rights to dividends or proceeds from the securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/12/2026 - 10:29 AM Accepted by SEC EDGAR 08/12/2026 - 10:28 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Hemab Therapeutics Holdings, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

423494103

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 423494103

1

Names of Reporting Persons

Capital International Investors

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,603,876.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,603,876.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,603,876.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Hemab Therapeutics Holdings, Inc.
(b)	Address of issuer's principal executive offices: 101 MAIN STREET, SUITE 1220, CAMBRIDGE, MA 02142
Item 2.
(a)	Name of person filing: Capital International Investors
(b)	Address or principal business office or, if none, residence: 333 South Hope Street, 55th Fl, Los Angeles, CA 90071
(c)	Citizenship: N/A
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 423494103
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 3,603,876 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 3,603,876 shares or 7.7% of the 46,705,410 shares believed to be outstanding.
(b)	Percent of class: 7.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,603,876
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,603,876
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. SMALLCAP World Fund, Inc.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Capital International Investors

Signature:	Aaron Espin
Name/Title:	Senior Vice President
Date:	07/29/2026